TR201007106A1 - Cefpodoxime proxetil formulations. - Google Patents

Cefpodoxime proxetil formulations.

Info

Publication number
TR201007106A1
TR201007106A1 TR2010/07106A TR201007106A TR201007106A1 TR 201007106 A1 TR201007106 A1 TR 201007106A1 TR 2010/07106 A TR2010/07106 A TR 2010/07106A TR 201007106 A TR201007106 A TR 201007106A TR 201007106 A1 TR201007106 A1 TR 201007106A1
Authority
TR
Turkey
Prior art keywords
formulations
cefpodoxime proxetil
proxetil
cefpodoxime
relates
Prior art date
Application number
TR2010/07106A
Other languages
Turkish (tr)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2010/07106A priority Critical patent/TR201007106A1/en
Priority to PCT/TR2011/000200 priority patent/WO2012026907A2/en
Priority to EP11782258.5A priority patent/EP2608776A2/en
Publication of TR201007106A1 publication Critical patent/TR201007106A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

Mevcut buluş, sefpodoksim proksetil içeren farmasötik formülasyonlara ilişkindir.The present invention relates to pharmaceutical formulations containing cefpodoxime proxetil.

TR2010/07106A 2010-08-25 2010-08-25 Cefpodoxime proxetil formulations. TR201007106A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2010/07106A TR201007106A1 (en) 2010-08-25 2010-08-25 Cefpodoxime proxetil formulations.
PCT/TR2011/000200 WO2012026907A2 (en) 2010-08-25 2011-08-24 Cefpodoxime proxetil formulations
EP11782258.5A EP2608776A2 (en) 2010-08-25 2011-08-24 Cefpodoxime proxetil formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/07106A TR201007106A1 (en) 2010-08-25 2010-08-25 Cefpodoxime proxetil formulations.

Publications (1)

Publication Number Publication Date
TR201007106A1 true TR201007106A1 (en) 2012-03-21

Family

ID=44947169

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/07106A TR201007106A1 (en) 2010-08-25 2010-08-25 Cefpodoxime proxetil formulations.

Country Status (3)

Country Link
EP (1) EP2608776A2 (en)
TR (1) TR201007106A1 (en)
WO (1) WO2012026907A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103142506B (en) * 2013-04-03 2015-02-25 天津医药集团津康制药有限公司 Cefpodoxime proxetil granules and preparation method thereof
CN103230367B (en) * 2013-05-07 2014-11-12 山东罗欣药业集团股份有限公司 Cefpodoxime proxetil composition dry suspension and preparation method thereof
CN107693491B (en) * 2017-04-20 2020-06-30 广东金城金素制药有限公司 Pharmaceutical composition and preparation for children
CN108815130A (en) * 2018-08-27 2018-11-16 邓倩 A kind of Cefpodoxime Proxetil tablet and its production technology

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486425A (en) 1980-09-30 1984-12-04 Sankyo Company Limited 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
ATE303149T1 (en) * 2001-02-27 2005-09-15 Ranbaxy Lab Ltd ORAL PHARMACEUTICAL COMPOSITION OF CEFPODOXIM PROXETIL
TW200404550A (en) * 2002-07-08 2004-04-01 Sankyo Co Cepharospolin formulation for oral use
CN1681497A (en) * 2002-07-16 2005-10-12 兰贝克赛实验室有限公司 Dispersible tablets for oral administration
EP1883393A2 (en) * 2005-05-05 2008-02-06 Lupin Ltd. Stabilized oral pharmaceutical compositions of cephalosporins
TR201002878A2 (en) * 2010-04-13 2011-10-21 Bi̇lgi̇ç Mahmut Pharmaceutical compositions comprising cefpodoxime proxetil.

Also Published As

Publication number Publication date
WO2012026907A2 (en) 2012-03-01
WO2012026907A3 (en) 2012-09-13
EP2608776A2 (en) 2013-07-03

Similar Documents

Publication Publication Date Title
JOP20180102B1 (en) Pharmaceutical composition
UA107791C2 (en) Pesticidal compositions
IN2012DN06714A (en)
IN2015DN00960A (en)
IN2014DN09346A (en)
MX2013002264A (en) Pesticidal compositions.
CL2012002979A1 (en) N3-substituted-n1-sulfonyl-5-fluorpyrimidinone derivatives.
EA201590887A1 (en) COMPOSITION
UY34582A (en) ANTI-CXCR3 ANTIBODIES
TR201821285T4 (en) Pharmaceutical formulations containing a CCR3 antagonist.
EA201491195A1 (en) METHOD FOR OBTAINING A COMPOSITION CONTAINING GALACT-OLIGOSACCHARIDES
TR201905787T4 (en) Lyophilized TAT-NR2B9C formulation.
EA201270256A1 (en) DERIVATIVES OF T1-SUBSTITUTED 5-FLUOR-2-OXOPYRIMIDINON-1 (2H) -KARBOXAMID
CL2014000815A1 (en) Compounds derived from insecticidal 2-methoxybenzamides; insecticidal compositions
EA201300733A1 (en) RECOMBINANT MICOBACTERIA AS A VACCINE
CO6761388A2 (en) Pharmaceutical compositions comprising alisporivir
TR201007106A1 (en) Cefpodoxime proxetil formulations.
TR201002878A2 (en) Pharmaceutical compositions comprising cefpodoxime proxetil.
TR201009168A2 (en) Water dispersible cefpodoxime proxetil formulations.
BR112013000941A2 (en) 14-epi-analog formulations of vitamin d
BR112013016029A2 (en) phosphomycin pharmaceutical composition.
TR201109160A2 (en) New pharmaceutical compositions containing eplerenone.
WO2012004073A3 (en) Use of beta-isophorone as solvent
IT1406067B1 (en) EUDERMIC COMPOSITIONS.
TR201007107A1 (en) Formulations of cefpodoxime proxetil containing taste regulating agent.